Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Taysha Gene Therapies (TSHA) has 4 years of Current Deferred Revenue data on file, last reported at $5.5 million in Q3 2025.

• For the quarter ending Q3 2025, Current Deferred Revenue fell 53.37% year-over-year to $5.5 million; the trailing twelve-month figure through Sep 2025 stood at $5.5 million (down 53.37% YoY), and the FY2024 full-year result was $9.8 million, down 46.02% from the prior year.
• Current Deferred Revenue held at $5.5 million in Q3 2025, from $5.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $33.6 million in Q4 2022 to a low of $5.5 million in Q2 2025.
• A 4-year average of $15.7 million and a median of $14.1 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 32.9% in 2024 and slumped 59.51% in 2025, its largest moves.
• Tracing TSHA's Current Deferred Revenue over 4 years: stood at $33.6 million in 2022, then tumbled by 46.04% to $18.1 million in 2023, then tumbled by 46.02% to $9.8 million in 2024, then plunged by 43.72% to $5.5 million in 2025.
• Business Quant data shows TSHA's Current Deferred Revenue at $5.5 million in Q3 2025, $5.5 million in Q2 2025, and $7.5 million in Q1 2025.